Literature DB >> 21459003

In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.

Judit Bartalis1, Fathi T Halaweish.   

Abstract

The aim of this study was to evaluate cucurbitacins (Cucs) liver protective activity in vitro and conduct QSAR studies against lipophilicity and ab initio descriptors. Nine Cucs were isolated from Cucurbitaceae plants and eight prepared by C2-alkylation or C16-acylation. Ten Cucs demonstrated protective activity on human hepatocyte-derived HepG2 cells exposed to CCl(4) (EC(50)=2.4-45.3 μM) with good margin to toxicity (T/A). All Cucs exhibited anti-proliferative effect on serum-activated rat stellate cells, HSC-T6 (EC(50)=0.02-4.12 μM) with high T/A. While silybin is nontoxic, its protection is lower compared to Cuc D (3), iso-D (4), I (5), B (11), E (12), I-Me (6), L-Me (7), and E-Me (13) on both cell lines. Strong correlations were found for lipophilicity with both protection and toxicity on HepG2. Lipophilicity correlated only with toxicity on HSC-T6. Consequently, we suggest that Cucs are potential hepatoprotective agents against fibrosis that deserve further examination. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459003     DOI: 10.1016/j.bmc.2011.01.037

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Development of Whole Genome SNP-CAPS Markers and Preliminary QTL Mapping of Fruit Pedicel Traits in Watermelon.

Authors:  Sikandar Amanullah; Benjamin Agyei Osae; Tiantian Yang; Shenglong Li; Farhat Abbas; Shi Liu; Shusen Liu; Zhengfeng Song; Xuezheng Wang; Peng Gao; Feishi Luan
Journal:  Front Plant Sci       Date:  2022-05-09       Impact factor: 6.627

2.  Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.

Authors:  Fardous F El-Senduny; Farid A Badria; Ahmed M El-Waseef; Subhash C Chauhan; Fathi Halaweish
Journal:  Tumour Biol       Date:  2015-08-05

3.  A Bioreductive Prodrug of Cucurbitacin B Significantly Inhibits Tumor Growth in the 4T1 Xenograft Mice Model.

Authors:  Parichat Suebsakwong; Jie Wang; Phorntip Khetkam; Natthida Weerapreeyakul; Jing Wu; Yun Du; Zhu-Jun Yao; Jian-Xin Li; Apichart Suksamrarn
Journal:  ACS Med Chem Lett       Date:  2019-09-10       Impact factor: 4.345

4.  Poisson parameters of antimicrobial activity: a quantitative structure-activity approach.

Authors:  Radu E Sestraş; Lorentz Jäntschi; Sorana D Bolboacă
Journal:  Int J Mol Sci       Date:  2012-04-24       Impact factor: 6.208

5.  Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer.

Authors:  Mohammed Sikander; Bilal Bin Hafeez; Shabnam Malik; Abdulrhman Alsayari; Fathi T Halaweish; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

6.  Rearranged lanostane-type triterpenoids with anti-hepatic fibrosis activities from Ganoderma applanatum.

Authors:  Lei Li; Xing-Rong Peng; Jin-Run Dong; Shuang-Yang Lu; Xiao-Nian Li; Lin Zhou; Ming-Hua Qiu
Journal:  RSC Adv       Date:  2018-09-05       Impact factor: 3.361

7.  RNA interference against discoidin domain receptor 2 ameliorates alcoholic liver disease in rats.

Authors:  Zheng Luo; Huimin Liu; Xiaomeng Sun; Rong Guo; Ruibing Cui; Xiangxing Ma; Ming Yan
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

8.  Community Pharmacists' Knowledge, Attitudes, and Practice of Herbal Medicines in Asir Region, Kingdom of Saudi Arabia.

Authors:  Abdulrhman Alsayari; Dalia Almghaslah; Arwa Khaled; Sivakumar Annadurai; Mona Ali Alkhairy; Hagar Abdulhadi Alqahtani; Boshra Abduh Alsayed; Rawabi Mohammed Alasiri; Abeer Mohammed Assiri
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-30       Impact factor: 2.629

9.  Isolation of anticancer constituents from Cucumis prophetarum var. prophetarum through bioassay-guided fractionation.

Authors:  Abdulrhman Alsayari; Lucas Kopel; Mahmoud Salama Ahmed; Hesham S M Soliman; Sivakumar Annadurai; Fathi T Halaweish
Journal:  BMC Complement Altern Med       Date:  2018-10-09       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.